Image_2_Carbamazepine Induces Focused T Cell Responses in Resolved Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Cases But Does Not Perturb the Immunopeptidome for T Cell Recognition.tif
Antiseizure medications (ASMs) are frequently implicated in T cell-mediated drug hypersensitivity reactions and cause skin tropic pathologies that range in severity from mild rashes to life-threatening systemic syndromes. During the acute stages of the more severe manifestations of these reactions, drug responsive proinflammatory CD8+ T cells display classical features of Th1 cytokine production (e.g. IFNγ) and cytolysis (e.g. granzyme B, perforin). These T cells may be found locally at the site of pathology (e.g. blister cells/fluid), as well as systemically (e.g. blood, organs). What is less understood are the long-lived immunological effects of the memory T cell pool following T cell-mediated drug hypersensitivity reactions. In this study, we examine the ASM carbamazepine (CBZ) and the CBZ-reactive memory T cell pool in patients who have a history of either Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) from 3-to-20 years following their initial adverse reaction. We show that in vitro drug restimulation of CBZ-reactive CD8+ T cells results in a proinflammatory profile and produces a mainly focused, yet private, T cell receptor (TCR) usage amongst human leukocyte antigen (HLA)-B*15:02-positive SJS or TEN patients. Additionally, we show that expression of these CBZ-reactive TCRs in a reporter cell line, lacking endogenous αβTCR, recapitulates the features of TCR activation reported for ASM-treated T cell lines/clones, providing a useful tool for further functional validations. Finally, we conduct a comprehensive evaluation of the HLA-B*15:02 immunopeptidome following ASM (or a metabolite) treatment of a HLA-B*15:02-positive B-lymphoblastoid cell line (C1R.B*15:02) and minor perturbation of the peptide repertoire. Collectively, this study shows that the CBZ-reactive T cells characterized require both the drug and HLA-B*15:02 for activation and that reactivation of memory T cells from blood results in a focused private TCR profile in patients with resolved disease.
History
References
- https://doi.org//10.1016/j.jid.2018.04.027
- https://doi.org//10.1056/NEJM199411103311906
- https://doi.org//10.4103/ijd.IJD_582_17
- https://doi.org//10.1016/S0140-6736(07)60460-7
- https://doi.org//10.1212/01.WNL.0000156354.20227.F0
- https://doi.org//10.1111/tan.13530
- https://doi.org//10.1038/428486a
- https://doi.org//10.4103/0378-6323.57718
- https://doi.org//10.1001/jamadermatol.2013.4114
- https://doi.org//10.1111/j.1528-1167.2010.02533.x
- https://doi.org//10.1111/j.1528-1167.2009.02269.x
- https://doi.org//10.1111/j.1528-1167.2010.02766.x
- https://doi.org//10.1016/j.eplepsyres.2011.08.010
- https://doi.org//10.1111/j.1742-7843.2012.00868.x
- https://doi.org//10.1038/tpj.2013.40
- https://doi.org//10.1016/j.jdermsci.2013.10.003
- https://doi.org//10.1097/01.fpc.0000199500.46842.4a
- https://doi.org//10.1056/NEJMoa1013297
- https://doi.org//10.1093/hmg/ddq537
- https://doi.org//10.1111/all.13821
- https://doi.org//10.1016/j.jaci.2011.12.990
- https://doi.org//10.1038/nature11147
- https://doi.org//10.1155/2018/5086503
- https://doi.org//10.1038/s41467-019-11396-2
- https://doi.org//10.1016/j.coi.2016.05.003
- https://doi.org//10.1073/pnas.1207934109
- https://doi.org//10.1097/QAD.0b013e328355fe8f
- https://doi.org//10.1016/j.jaci.2011.08.013
- https://doi.org//10.1016/j.jim.2014.01.013
- https://doi.org//10.1016/j.molimm.2019.01.002
- https://doi.org//10.1021/tx400460w
- https://doi.org//10.1111/epi.12217
- https://doi.org//10.1212/WNL.0000000000004008
- https://doi.org//10.1097/TP.0b013e3181ff4ff3
- https://doi.org//10.1126/scitranslmed.3003647
- https://doi.org//10.1093/nar/gkn316
- https://doi.org//10.1159/000019140
- https://doi.org//10.1038/nbt957
- https://doi.org//10.4049/jimmunol.1303147
- https://doi.org//10.1038/s41596-019-0133-y
- https://doi.org//10.1038/s41590-019-0320-6
- https://doi.org//10.1002/pmic.201100463
- https://doi.org//10.1093/nar/gky1106
- https://doi.org//10.1101/gr.092759.109
- https://doi.org//10.1016/j.jaci.2007.06.017
- https://doi.org//10.1016/j.jaci.2015.05.050
- https://doi.org//10.1016/j.jaci.2006.03.005
- https://doi.org//10.1124/mol.63.3.732
- https://doi.org//10.1067/mai.2003.1507
- https://doi.org//10.1016/j.eplepsyres.2008.04.003
- https://doi.org//10.1212/01.wnl.0000334295.50403.4c
- https://doi.org//10.1017/S0317167100021880
- https://doi.org//10.1016/j.seizure.2010.09.003
- https://doi.org//10.1016/S1081-1206(10)61103-9
- https://doi.org//10.1172/JCI99321
- https://doi.org//10.4049/jimmunol.2000249
- https://doi.org//10.3389/fimmu.2020.00248
Usage metrics
Read the peer-reviewed publication
Categories
- Transplantation Immunology
- Tumour Immunology
- Immunology not elsewhere classified
- Immunology
- Veterinary Immunology
- Animal Immunology
- Genetic Immunology
- Applied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies)
- Autoimmunity
- Cellular Immunology
- Humoural Immunology and Immunochemistry
- Immunogenetics (incl. Genetic Immunology)
- Innate Immunity